Results 101 to 110 of about 626,377 (227)

Targeted delivery of the CB2 receptor agonist JWH‐133 via VCAM‐1‐functionalised nanoparticles attenuates atherosclerosis and reveals sex‐specific therapeutic outcomes

British Journal of Pharmacology, EarlyView.
Background and Purpose Atherosclerosis, a chronic inflammatory disease characterised by lipid accumulation and endothelial dysfunction, remains a leading cause of cardiovascular morbidity and mortality. While cannabinoid 2 (CB2) receptor agonists show therapeutic promise in preclinical studies, their systemic application is hindered by poor ...
Lucía Martín‐Navarro, Lucía Martín‐Banderas, Josefa Álvarez‐Fuentes, María Dolores Herrera‐González   +3 more
wiley   +1 more source

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Oral PCSK9 Inhibitors: Will They Work?

Purpose of ReviewLowering low-density lipoprotein cholesterol (LDL-C) is a crucial step in reducing the risk of atherosclerotic cardiovascular disease.
Pirillo, Angela, Tokgozoglu, Lale, Catapano, Alberico L.   +2 more
core   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Role of PCSK9 on vascular calcification: study of an uremic mouse model

, 2022
reservedLa patologia cardiovascolare è la prima causa di morbilità e mortalità nei pazienti affetti da malattia renale cronica (CKD). Una funzione renale compromessa comporta un’alterazione del profilo lipidico e in associazione con elevati livelli ...
RIZZATO, MARTINA
core  

Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis

The Egyptian Heart Journal
Background Acute coronary syndrome continues to be a significant cardiovascular issue. Statins are commonly acknowledged as medications that reduce LDL-C levels and stabilize plaques. Nevertheless, their efficacy is limited.
Dennis Ievan Hakim, Faqrizal Ria Qhabibi, Muhammad Yusuf, Nasim Amar, Indra Prasetya, Ade Meidian Ambari   +5 more
doaj   +1 more source

Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Genetic clusters related to Type 2 diabetes (T2D) have differential impact on cardiovascular diseases (CVDs), although the underlying mechanisms, such as proteomic perturbation, remain unexplored. We conducted a network Mendelian randomisation (MR) study to identify proteomic mediators linking T2D genetic clusters and CVDs.
Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang, Chenxi Li, Shiu Lun Au Yeung   +4 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Use of PCSK9-Inhibitors

, 2020
Hintergrund Nach Entdeckung des Enzyms Proprotein Convertase Subtilisin-like Kexin Type 9 (PCSK9) und dessen Bedeutung für die Präsenz von LDL-Rezeptoren auf der Hepatozytenoberfläche, wurden 2015 die beiden PCSK9-Inhibitoren Evolocumab (Repatha®) und ...
Pasteiner, Martina
core  

Pharmacological Targets for Periodontitis: A Systematic Review of Drug‐Target Mendelian Randomisation Studies

Journal of Periodontal Research, EarlyView.
This systematic review evaluated drug‐target Mendelian randomisation studies on periodontitis. Twelve studies identified host‐response‐related targets mainly involved in inflammatory, complement, and immune pathways. Although some targets were linked to existing drugs, the evidence remains preliminary and heterogeneous, requiring replication and ...
Luigi Nibali, Jing Kang, Simon Haworth, Alessandro Polizzi, Gaetano Isola   +4 more
wiley   +1 more source